VANCOUVER, BC / ACCESS Newswire / November 4, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, ...

MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower ...

The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of ...

New deal builds on the success of a longstanding partnership in retinal health and the potential of CDR-Life’s unique antibody fragment-based ...

Presented recent updates on fibroblast-based therapies for chronic disease treatments at the Cell & Gene Meeting on the Mesa, H.C. Wainwright 27th Annual Global Investment Conference, and the 2025 ...

Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients Prepa ...

TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.

Discover the pros and cons of maintaining an MS symptom diary. Learn how it can aid in identifying relapses and triggers, improve doctor communication, but also cause stress for some.

TG Therapeutics (NASDAQ: TGTX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate TG Therapeutics to ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along with recent ...

The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001 ...

Calum Richardson revealed earlier this year that watching his older sister Karen battle multiple sclerosis made him realise ...